Want to see IT:FDA full AI Analyst Report?
FDA Stock Chart & Stats
€0.12
>-€0.01(-6.28%)
At close: 4:00 PM EST
€0.12
>-€0.01(-6.28%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.39
Previous CloseN/A
Volume4.67M
Average Volume (3M)597.93K
Market Cap
€9.75M
Enterprise Value-€365.91K
Total Cash (Recent Filing)€2.44M
Total Debt (Recent Filing)€5.24M
Price to Earnings (P/E)―
Beta0.95
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,249,412,000
10 Day Avg. Volume275,058
30 Day Avg. Volume597,935
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.28
Price to Sales (P/S)0.60
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe sharp 2025 rebound indicates recovering demand and renewed commercial traction. Sustaining this higher revenue base could improve operating leverage, broaden funding capacity, and support investment in products and geographic expansion.
Improved Balance SheetThe move from negative equity in 2020–2021 to a positive capital base reduces immediate balance-sheet pressure. Relatively modest debt also provides more flexibility to fund operations and commercial development than in prior years.
Integrated Healthcare PlatformControl across research, production, and commercialization can support product quality, supply coordination, and margin capture. Direct sales combined with partners also gives Fidia multiple routes to expand in joint health and related medical markets.
Bears Say
Persistent Cash BurnThree consecutive years of negative operating and free cash flow weaken self-funding capacity. Unless working capital and profitability improve, Fidia may need additional financing, asset sales, or tighter investment to sustain operations.
Unstable ProfitabilityThe return to net income is encouraging, but repeated operating losses and large margin swings indicate that earnings quality remains unproven. This limits confidence that revenue growth will translate into durable profits and cash generation.
Volatile Leverage HistoryAlthough current debt is modest and equity is positive, prior leverage volatility shows that the capital structure can weaken quickly when earnings deteriorate. Continued cash losses could therefore erode the recent balance-sheet improvement.
Fidia Spa News
FDA FAQ
What was Fidia Spa’s price range in the past 12 months?
Fidia Spa lowest stock price was <€0.01 and its highest was €0.39 in the past 12 months.
What is Fidia Spa’s market cap?
Fidia Spa’s market cap is €9.75M.
When is Fidia Spa’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Fidia Spa’s earnings last quarter?
Currently, no data Available
Is Fidia Spa overvalued?
According to Wall Street analysts Fidia Spa’s price is currently Overvalued.
Does Fidia Spa pay dividends?
Fidia Spa pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Fidia Spa dividends here
What is Fidia Spa’s EPS estimate?
Fidia Spa’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fidia Spa have?
Fidia Spa has 1,249,412,000 shares outstanding.
What happened to Fidia Spa’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fidia Spa?
Currently, no hedge funds are holding shares in IT:FDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fidia Spa
Fidia S.p.A., together with its affiliated entities, focuses on engineering, producing, and supplying advanced high-speed milling systems and computerized numerical control (CNC) machines. Their product range also incorporates specialized milling heads, accompanying software, and various peripheral devices. Among these accessories, the HMS system is engineered for precise measurement and compensation of geometric errors in continuous or indexed bi-rotary heads and roto-tilting tables. The TMSC device accurately determines tool length and diameter, in addition to verifying its overall geometry. The K5 tracer provides a seamless solution for continuous scanning of three-dimensional surfaces. Other components include user-friendly pushbutton panels, XPower digital drives that control axis and spindle movement, and I/O Line input/output modules. Fidia's extensive software suite features ViMill, an anti-collision safeguard; HiMonitor, which tracks machine operational status; and Velocity 5, a system designed to optimize axis control, thereby enhancing machine performance. The HiMill computer-aided manufacturing (CAM) software is dedicated to the fabrication of dies, models, and aerospace components. An intuitive user interface is offered through the Isograph solution, while procedure-PRX provides tailored automation capabilities. The company serves critical sectors such as the automotive, aerospace, and power generation industries. Fidia's global presence covers Italy, the wider European continent, Asia, and both North and South America. Established in 1974, Fidia S.p.A. maintains its corporate headquarters in San Mauro Torinese, Italy.
Technical Analysis
Biesse SPA
―
Interpump Group SPA
―
Tesmec S.p.A.
―
Esautomotion SpA
―
Marzocchi Pompe S.p.A.
―